A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome

Archives of Internal Medicine

Volumn 161, Issue 14, 2001, Pages 1733-1740

  Camilleri, Michael ^a   Chey, William Y ^b   Mayer, Emeran A ^c   Northcutt, Allison R ^d   Heath, Amy ^d   Dukes, George E ^d   McSorley, David ^d   Mangel, Allen M ^d  

^a MAYO CLINIC   (United States)

^b Rochester Institute for Digestive Diseases and Sciences   (United States)

^c UCLA MEDICAL CENTER   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; PLACEBO; SEROTONIN 3 ANTAGONIST;

ABDOMINAL DISCOMFORT; ADULT; ANALGESIA; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FECES ANALYSIS; FEMALE; HUMAN; IRRITABLE COLON; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0034917335     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.161.14.1733     Document Type: Article

References (47)

1. Irritable bowel syndrome in office-based practice in the United States
2. A national survey of practice patterns of gastroenterologists with comparison to the past two decades
3. Irritable bowel syndrome: Definition, diagnosis and epidemiology
4. Irritable bowel syndrome: A technical review for practice guideline development
5. Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom
6. Quality of life in persons with irritable bowel syndrome: Development and validation of a new measure
7. Impact of irritable bowel syndrome on quality of life
8. Clinical economics review: Irritable bowel syndrome
9. Functional bowel disorders and functional abdominal pain
10. Roles played by 5-hydroxytryptamine in the physiology of the bowel
11. Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome
12. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome
13. Visceral perception in irritable bowel syndrome: Rectal and gastric responses to distension and serotonin type 3 antagonism
14. Selective 5-hydroxytryptamine antagonism: A role in irritable bowel syndrome and functional dyspepsia?
15. Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron)
16. A double-blind placebo -controlled study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome
17. Improvement in pain and bowel function in female irritable bowel syndrome patients with alosetron, a 5-HT3-receptor antagonist
18. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients
19. The efficacy and safety of alosetron in female patients with irritable bowel syndrome: A randomised, placebo controlled study
20. Controlled treatment trials in the irritable bowel syndrome: A critique
21. Irritable bowel syndrome clinical trial design: Future needs
22. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome
23. Validation of adequate relief as an endpoint in irritable bowel syndrome
24. Functional bowel disorders and functional abdominal pain
25. Use of a novel electronic data collection system in multicenter studies of irritable bowel syndrome
26. Statistical aspects of the analysis of data from retrospective studies of diseases
27. On the combination of independent two sample tests of Wilcoxon
28. Procedures for comparing samples with multiple endpoints
29. Procedures for two-sample comparisons with multiple endpoints: Controlling the experimentwise error rate
30. Symptom differences in moderate to severe IBS patients based on predominant bowel habit
31. Sex differences in pain
32. Gender differences in brain regions associated with subjective intensity ratings of visceral stimuli
33. Variability of gastrointestinal transit in healthy women and men
34. Gender differences in bowel function
35. Evidence of gender differences in esophageal pain threshold
36. Alosetron retards small bowel and overall colonic transit in diarrhea-predominant irritable bowel syndrome (D-lBS)
37. Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life
38. Non-colonic features of irritable bowel syndrome
39. Psychosocial aspects of functional gastrointestinal disorders
40. Urgency as an endpoint in IBS
41. Design of treatment trials for functional gastrointestinal disorders
42. Alosetron, a 5-HT-3 receptor antagonist, delays colonic transit in patients with IBS and healthy volunteers
43. The effects of granisetron, ICS 205-930 and ondansetron on the visceral pain reflex induced by duodenal distension
44. Differences between 5-HT3 receptor antagonists in modulation of visceral hypersensitivity
45. Central modulation of rectal distension-induced blood pressure changes by alosetron, a 5-HT3 receptor antagonist
46. Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist